Nifedipine, but not verapamil, acutely elevates parathyroid hormone levels in premenopausal women

A. G. Wynne, S. A. Romanski, G. G. Klee, S. J. Ory, W. M. O'Fallon, L. A. Fitzpatrick

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Calcium channel antagonist therapy in humans has been associated with changes in anterior pituitary, thyroid and adrenal hormone secretion. Human studies assessing effects of calcium channel antagonists on calciotropic hormones have been few and typically involved small numbers of subjects studied for short periods of time. Few of these previously published studies have included women. The endocrine effects of calcium channel antagonists in women have become increasingly important as more women are taking these agents for diseases such as hypertension, angina, Raynaud's phenomenon and migraine. Objective: To assess both acute and chronic effects of calcium channel antagonists on calciotropic hormones in women. Design: A four-week prospective, randomized trial. Subjects: Twenty-nine premenopausal women, randomly assigned to receive either 240 mg of sustained release verapamil or 30 mg of sustained release nifedipine daily. Laboratory end-points: Total and ionized serum calcium, phosphate, creatinine, parathyroid hormone (pTH), parathyroid hormone-related protein (pTHrP) and calcitonin, measured at baseline, after 24 hours, and 28 days of treatment. Results: Total and ionized calcium, phosphate, creatinine, pTHrP and calcitonin levels were not altered significantly after 24 hours or 28 days in any of the subjects, when compared to baseline. There were no significant differences in PTH levels after 24 hours or 28 days of verapamil treatment. There was a significant increase in serum PTH levels after 24 hours of nifedipine therapy; however, these differences were not evident after 28 days of therapy. Conclusions: The short-term administration of nifedipine results in increased release of parathyroid hormone; however, long-term administration has no significant effect on the concentrations of calciotropic hormones.

Original languageEnglish (US)
Pages (from-to)9-15
Number of pages7
JournalClinical Endocrinology
Volume42
Issue number1
StatePublished - 1995

Fingerprint

Nifedipine
Verapamil
Parathyroid Hormone
Calcium Channel Blockers
Parathyroid Hormone-Related Protein
Calcitonin
Hormones
Creatinine
Therapeutics
Raynaud Disease
Serum
Migraine Disorders
Thyroid Hormones
Hypertension
calcium phosphate

ASJC Scopus subject areas

  • Endocrinology

Cite this

Wynne, A. G., Romanski, S. A., Klee, G. G., Ory, S. J., O'Fallon, W. M., & Fitzpatrick, L. A. (1995). Nifedipine, but not verapamil, acutely elevates parathyroid hormone levels in premenopausal women. Clinical Endocrinology, 42(1), 9-15.

Nifedipine, but not verapamil, acutely elevates parathyroid hormone levels in premenopausal women. / Wynne, A. G.; Romanski, S. A.; Klee, G. G.; Ory, S. J.; O'Fallon, W. M.; Fitzpatrick, L. A.

In: Clinical Endocrinology, Vol. 42, No. 1, 1995, p. 9-15.

Research output: Contribution to journalArticle

Wynne, AG, Romanski, SA, Klee, GG, Ory, SJ, O'Fallon, WM & Fitzpatrick, LA 1995, 'Nifedipine, but not verapamil, acutely elevates parathyroid hormone levels in premenopausal women', Clinical Endocrinology, vol. 42, no. 1, pp. 9-15.
Wynne AG, Romanski SA, Klee GG, Ory SJ, O'Fallon WM, Fitzpatrick LA. Nifedipine, but not verapamil, acutely elevates parathyroid hormone levels in premenopausal women. Clinical Endocrinology. 1995;42(1):9-15.
Wynne, A. G. ; Romanski, S. A. ; Klee, G. G. ; Ory, S. J. ; O'Fallon, W. M. ; Fitzpatrick, L. A. / Nifedipine, but not verapamil, acutely elevates parathyroid hormone levels in premenopausal women. In: Clinical Endocrinology. 1995 ; Vol. 42, No. 1. pp. 9-15.
@article{64ce95d38fc94bd7b9b819007861bcdd,
title = "Nifedipine, but not verapamil, acutely elevates parathyroid hormone levels in premenopausal women",
abstract = "Background: Calcium channel antagonist therapy in humans has been associated with changes in anterior pituitary, thyroid and adrenal hormone secretion. Human studies assessing effects of calcium channel antagonists on calciotropic hormones have been few and typically involved small numbers of subjects studied for short periods of time. Few of these previously published studies have included women. The endocrine effects of calcium channel antagonists in women have become increasingly important as more women are taking these agents for diseases such as hypertension, angina, Raynaud's phenomenon and migraine. Objective: To assess both acute and chronic effects of calcium channel antagonists on calciotropic hormones in women. Design: A four-week prospective, randomized trial. Subjects: Twenty-nine premenopausal women, randomly assigned to receive either 240 mg of sustained release verapamil or 30 mg of sustained release nifedipine daily. Laboratory end-points: Total and ionized serum calcium, phosphate, creatinine, parathyroid hormone (pTH), parathyroid hormone-related protein (pTHrP) and calcitonin, measured at baseline, after 24 hours, and 28 days of treatment. Results: Total and ionized calcium, phosphate, creatinine, pTHrP and calcitonin levels were not altered significantly after 24 hours or 28 days in any of the subjects, when compared to baseline. There were no significant differences in PTH levels after 24 hours or 28 days of verapamil treatment. There was a significant increase in serum PTH levels after 24 hours of nifedipine therapy; however, these differences were not evident after 28 days of therapy. Conclusions: The short-term administration of nifedipine results in increased release of parathyroid hormone; however, long-term administration has no significant effect on the concentrations of calciotropic hormones.",
author = "Wynne, {A. G.} and Romanski, {S. A.} and Klee, {G. G.} and Ory, {S. J.} and O'Fallon, {W. M.} and Fitzpatrick, {L. A.}",
year = "1995",
language = "English (US)",
volume = "42",
pages = "9--15",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Nifedipine, but not verapamil, acutely elevates parathyroid hormone levels in premenopausal women

AU - Wynne, A. G.

AU - Romanski, S. A.

AU - Klee, G. G.

AU - Ory, S. J.

AU - O'Fallon, W. M.

AU - Fitzpatrick, L. A.

PY - 1995

Y1 - 1995

N2 - Background: Calcium channel antagonist therapy in humans has been associated with changes in anterior pituitary, thyroid and adrenal hormone secretion. Human studies assessing effects of calcium channel antagonists on calciotropic hormones have been few and typically involved small numbers of subjects studied for short periods of time. Few of these previously published studies have included women. The endocrine effects of calcium channel antagonists in women have become increasingly important as more women are taking these agents for diseases such as hypertension, angina, Raynaud's phenomenon and migraine. Objective: To assess both acute and chronic effects of calcium channel antagonists on calciotropic hormones in women. Design: A four-week prospective, randomized trial. Subjects: Twenty-nine premenopausal women, randomly assigned to receive either 240 mg of sustained release verapamil or 30 mg of sustained release nifedipine daily. Laboratory end-points: Total and ionized serum calcium, phosphate, creatinine, parathyroid hormone (pTH), parathyroid hormone-related protein (pTHrP) and calcitonin, measured at baseline, after 24 hours, and 28 days of treatment. Results: Total and ionized calcium, phosphate, creatinine, pTHrP and calcitonin levels were not altered significantly after 24 hours or 28 days in any of the subjects, when compared to baseline. There were no significant differences in PTH levels after 24 hours or 28 days of verapamil treatment. There was a significant increase in serum PTH levels after 24 hours of nifedipine therapy; however, these differences were not evident after 28 days of therapy. Conclusions: The short-term administration of nifedipine results in increased release of parathyroid hormone; however, long-term administration has no significant effect on the concentrations of calciotropic hormones.

AB - Background: Calcium channel antagonist therapy in humans has been associated with changes in anterior pituitary, thyroid and adrenal hormone secretion. Human studies assessing effects of calcium channel antagonists on calciotropic hormones have been few and typically involved small numbers of subjects studied for short periods of time. Few of these previously published studies have included women. The endocrine effects of calcium channel antagonists in women have become increasingly important as more women are taking these agents for diseases such as hypertension, angina, Raynaud's phenomenon and migraine. Objective: To assess both acute and chronic effects of calcium channel antagonists on calciotropic hormones in women. Design: A four-week prospective, randomized trial. Subjects: Twenty-nine premenopausal women, randomly assigned to receive either 240 mg of sustained release verapamil or 30 mg of sustained release nifedipine daily. Laboratory end-points: Total and ionized serum calcium, phosphate, creatinine, parathyroid hormone (pTH), parathyroid hormone-related protein (pTHrP) and calcitonin, measured at baseline, after 24 hours, and 28 days of treatment. Results: Total and ionized calcium, phosphate, creatinine, pTHrP and calcitonin levels were not altered significantly after 24 hours or 28 days in any of the subjects, when compared to baseline. There were no significant differences in PTH levels after 24 hours or 28 days of verapamil treatment. There was a significant increase in serum PTH levels after 24 hours of nifedipine therapy; however, these differences were not evident after 28 days of therapy. Conclusions: The short-term administration of nifedipine results in increased release of parathyroid hormone; however, long-term administration has no significant effect on the concentrations of calciotropic hormones.

UR - http://www.scopus.com/inward/record.url?scp=0028918909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028918909&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 9

EP - 15

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 1

ER -